Feedback / Questions
brivekimig (SAR442970) - Sanofi
Brivekimig: "Achieved primary objective in HS phase 2 study"; Hidradenitis Suppurativa
(Sanofi)
-
Oct 24, 2025 -
Q3 2025 Results
P2 data
•
Hidradenitis Suppurativa
https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2025/2025-q3-2025-results/2025_10_24_Sanofi_Q3_2025_Results.pdf
Oct 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious